A phase II trial of SYD985 for the treatment of HER2-positive endometrial cancer (NCT04205630) and a phase I trial of this drug in combination with niraparib (NCT04235101) for the treatment of HER2-positive solid tumors are currently ongoing. The gene discussed is ERBB2; the disease is endometrial cancer.